Zacks.com on MSN5d
TSVT Up on Acquisition Agreement With BMY for $286 MillionTSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...
Zacks Investment Research on MSN4d
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...
Fintel on MSN5d
Leerink Partners Downgrades 2seventy bio (TSVT)Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 2seventy bio, Inc. (NASDAQ: TSVT) to Bristol Myers Squibb for $5.00 per share is fair to 2seventy shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 2seventy bio, Inc. (NASDAQ: TSVT) to Bristol Myers Squibb for $5.0 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback